G Protein-coupled receptor 87: A promising opportunity for cancer drug discovery

Molecular and Cellular Pharmacology

Volumn 2, Issue 3, 2010, Pages 111-116

  Zhang, Yanhong ^a   Scoumanne, Ariane ^a   Chen, Xinbin ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Apoptosis; Cancer therapy; DNA damage; G protein coupled receptor 87 (GPR87); p53

Indexed keywords

ANTINEOPLASTIC AGENT; CELL SURFACE PROTEIN; DESLORATADINE; DNA; G PROTEIN COUPLED RECEPTOR; G PROTEIN COUPLED RECEPTOR 87; G PROTEIN COUPLED RECEPTOR 87 ANTAGONIST; GONADORELIN; GOSERELIN; LEUPRORELIN; LYSOPHOSPHATIDIC ACID RECEPTOR; MEMBRANE PROTEIN; OCTREOTIDE; PROTEIN KINASE B; PROTEIN P53; RANITIDINE; SOMATOSTATIN RECEPTOR; UNCLASSIFIED DRUG; VPC 32183; ZANTAX;

APOPTOSIS; ARTICLE; BREAST CANCER; CANCER INHIBITION; CANCER PREVENTION; CANCER THERAPY; CARCINOGENESIS; CARCINOMA; CELL SURFACE; CELL SURVIVAL; CELLULAR STRESS RESPONSE; DNA DAMAGE; DRUG MECHANISM; DRUG TARGETING; GENE EXPRESSION REGULATION; GENE OVEREXPRESSION; HUMAN; IMMUNITY; INFLAMMATION; LIGAND BINDING; LIVER CELL CARCINOMA; MENINGIOMA; NEUROTRANSMISSION; NONHUMAN; PANCREAS CARCINOMA; PROSTATE CANCER; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN LOCALIZATION; PROTEIN STRUCTURE; RECURRENT CANCER; SIGNAL TRANSDUCTION; TUMOR CELL; TUMOR SUPPRESSOR GENE;

EID: 77954267775     PISSN: None     EISSN: 19381247     Source Type: Journal    
DOI: 10.4255/mcpharmacol.10.15     Document Type: Article

References (40)

1. Pierce KL, Premont RT, Lefkowitz RJ. Seventransmembrane receptors. Nat Rev Mol Cell Biol 2002; 3: 639-50.
2. Ji TH, Grossmann M, Ji I. G protein-coupled receptors. I. Diversity of receptor-ligand interactions. J Biol Chem 1998; 273:17299-302.
3. Marinissen MJ, Gutkind JS. G-protein-coupled receptors and signaling networks: emerging paradigms. Trends Pharmacol Sci 2001; 22: 368-76.
4. Strader CD, Fong TM, Tota MR, et al. Structure and function of G protein-coupled receptors. Annu Rev Biochem 1994; 63:101-32.
5. Neves SR, Ram PT, Iyengar R. G protein pathways. Science 2002; 296: 1636-9.
6. Dorsam RT, Gutkind JS. G-protein-coupled receptors and cancer. Nat Rev Cancer 2007; 7: 79-94.
7. Coughlin SR. Expanding horizons for receptors coupled to G proteins: diversity and disease. Curr Opin Cell Biol 1994; 6: 191-7.
8. Spiegel AM, Weinstein LS. Inherited diseases involving g proteins and g protein-coupled receptors. Annu Rev Med 2004; 55: 27-39.
9. Nathans J, Hogness DS. Isolation, sequence analysis, and intron-exon arrangement of the gene encoding bovine rhodopsin. Cell 1983; 34: 807-14.
10. Kobilka BK. G protein coupled receptor structure and activation. Biochim Biophys Acta 2007; 1768: 794-807.
11. Oh DY, Kim K, Kwon HB, et al. Cellular and molecular biology of orphan G protein-coupled receptors. Int Rev Cytol 2006; 252: 163-218.
12. Wise A, Gearing K, Rees S. Target validation of G-protein coupled receptors. Drug Discov Today 2002; 7: 235-246.
13. Eglen RM, Bosse R, Reisine T. Emerging concepts of guanine nucleotide-binding protein-coupled receptor (GPCR) function and implications for high throughput screening. Assay Drug Dev Technol 2007; 5: 425-51
14. Li S, Huang S, Peng SB. Overexpression of G protein- coupled receptors in cancer cells: involvement in tumor progression. Int J Oncol 2005; 27: 1329-39.
15. Carmeci C, Thompson DA, Ring HZ, et al. Identification of a gene (GPR30) with homology to the G- protein-coupled receptor superfamily associated with estrogen receptor expression in breast cancer. Genomics 1997; 45: 607-17.
16. Fang X, Schummer M, Mao M, et al. Lysophosphatidic acid is a bioactive mediator in ovarian cancer. Biochim Biophys Acta 2002; 1582: 257-64.
17. Parma J, Duprez L, Van Sande J, et al. Somatic mutations in the thyrotropin receptor gene cause hyperfunctioning thyroid adenomas. Nature 1993; 365: 649-51.
18. Gnant M, Mlineritsch B, Schippinger W, et al. Endocrine therapy plus zoledronic acid in premenopausal breast cancer. N Engl J Med 2009; 360: 679-91.
19. Hejna M, Schmidinger M, Raderer M. The clinical role of somatostatin analogues as antineoplastic agents: much ado about nothing? Ann Oncol 2002; 13: 653-68.
20. Wittenberger T, Schaller HC, Hellebrand S. An expressed sequence tag (EST) data mining strategy succeeding in the discovery of new G-protein coupled receptors. J Mol Biol 2001; 307: 799-813.
21. Lee DK, Nguyen T, Lynch KR, et al. Discovery and mapping of ten novel G protein-coupled receptor genes. Gene 2001; 275: 83-91.
22. Glatt S, Halbauer D, Heindl S, et al. hGPR87 contributes to viability of human tumor cells. Int J Cancer 2008; 122: 2008-16.
23. Tabata K, Baba K, Shiraishi A, et al. The orphan GPCR GPR87 was deorphanized and shown to be a lysophosphatidic acid receptor. Biochem Biophys Res Commun 2007; 363: 861-6.
24. Zhang Y, Qian Y, Lu W, et al. The G protein-coupled receptor 87 is necessary for p53-dependent cell survival in response to genotoxic stress. Cancer Res 2009; 69: 6049-56.
25. Harris SL, Levine AJ. The p53 pathway: positive and negative feedback loops. Oncogene 2005; 24: 2899-908.
26. Harms K, Nozell S, Chen X. The common and distinct target genes of the p53 family transcription factors. Cell Mol Life Sci 2004; 61: 822-42.
27. Cheng Y, Lotan R. Molecular cloning and characterization of a novel retinoic acid-inducible gene that encodes a putative G protein-coupled receptor. J Biol Chem 1998; 273: 35008-15.
28. Nagahata T, Sato T, Tomura A, et al. Identification of RAI3 as a therapeutic target for breast cancer. Endocr Relat Cancer 2005; 12: 65-73.
29. Wu Q, Ding W, Mirza A, et al. Integrative genomics revealed RAI3 is a cell growth-promoting gene and a novel P53 transcriptional target. J Biol Chem 2005; 280: 12935-43.
30. Yang X, Taylor L, Polgar P. p53 down-regulates human bradykinin B1 receptor gene expression. J Cell Biochem 2001; 82: 38-45.
31. Marceau F, Larrivee JF, Saint-Jacques E, et al. The kinin B1 receptor: an inducible G protein coupled receptor. Can J Physiol Pharmacol 1997; 75: 725-30.
32. Saifudeen Z, Du H, Dipp S et al. The bradykinin type 2 receptor is a target for p53-mediated transcriptional activation. J Biol Chem 2000; 275: 15557-62.
33. Saifudeen Z, Diavolitsis V, Stefkova J, et al. Spatiotemporal switch from DeltaNp73 to TAp73 isoforms during nephrogenesis: impact on differentiation gene expression. J Biol Chem 2005; 280: 23094-102.
34. Kubo T, Ichimiya S, Tonooka A, et al. p63 induces CD4+ T-cell chemoattractant TARC/CCL17 in human epithelial cells. J Interferon Cytokine Res 2008; 28: 725-32.
35. New DC, Wu K, Kwok AW et al. G protein-coupled receptor-induced Akt activity in cellular proliferation and apoptosis. FEBS J 2007; 274: 6025-36.
36. Sabbatini P McCormick F. Phosphoinositide 3-OH kinase (PI3K) and PKB/Akt delay the onset of p53- mediated, transcriptionally dependent apoptosis. J Biol Chem 1999; 274: 24263-9.
37. Mayo LD, Donner DB. A phosphatidylinositol 3-kinase/Akt pathway promotes translocation of Mdm2 from the cytoplasm to the nucleus. Proc Natl Acad Sci 2001; 98: 11598-603.
38. Ogawara Y, Kishishita S, Obata T, et al. Akt enhances Mdm2-mediated ubiquitination and degradation of p53. J Biol Chem 2002; 277: 21843-50.
39. Murph MM, Hurst-Kennedy J, Newton V, et al. Lysophosphatidic acid decreases the nuclear localization and cellular abundance of the p53 tumor suppressor in A549 lung carcinoma cells. Mol Cancer Res 2007; 5: 1201-11.
40. Hurst-Kennedy J, Boyan BD, Schwartz Z. Lysophosphatidic acid signaling promotes proliferation, differentiation, and cell survival in rat growth plate chondrocytes. Biochim Biophys Acta 2009; 1793: 836-46.